The results from this network meta-analysis present important implications for public health when dealing with EGFR-mutated advanced NSCLC, especially regarding the superior OS and PFS of osimertinib compared to erlotinib-based regimens, which supports its position as the preferred first-line treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.